Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas
Open Access
- 1 February 1998
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 77 (4), 663-669
- https://doi.org/10.1038/bjc.1998.106
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia.1995
- Intratumor microvessel density as a prognostic factor in cancer.1995
- Structure and expression of the cyclin A gene in human primary liver cancer. Correlation with flow cytometric parametersJournal of Hepatology, 1995
- Cyclins as markers of tumor proliferation: immunocytochemical studies in breast cancer.Proceedings of the National Academy of Sciences, 1995
- Association of Vascular Endothelial Growth Factor Expression with Tumor Angiogenesis and with Early Relapse in Primary Breast CancerJapanese Journal of Cancer Research, 1994
- Analysis of c-fos, c-jun, c-erbB1, c-erbB2 and c-myc in primary lung carcinomas and their lymph node metastasesClinical & Experimental Metastasis, 1994
- IP-1: A dominant inhibitor of Fos/Jun whose activity is modulated by phosphorylationCell, 1991
- EXPRESSION OF RAS P21 AND MYC P62 ONCOPROTEINS IN SMALL-CELL AND NON-SMALL-CELL CARCINOMA OF THE LUNG1990
- fos-associated cellular p39 is related to nuclear transcription factor AP-1Cell, 1988
- IMMUNOCYTOCHEMICAL DETECTION OF A RESISTANCE-ASSOCIATED GLYCOPROTEIN IN TISSUE-CULTURE CELLS, ASCITES TUMORS AND HUMAN-TUMOR XENOGRAFTS BY MAB 265 F41988